NeuroOne Medical Technologies Corporation Appoints Dr. Camilo Andres Diaz-Botia, Former Lead of Process Engineering at Neuralink, as Director of Electrode Development
Eden Prairie, MN – NeuroOne Medical Technologies Corporation (OTCQB: NMTC) (NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces the appointment of Dr. Camilo Andres Diaz-Botia, a highly experienced neural engineer whose work has focused on the development of technologies for bidirectional communication with the nervous system, as Director of Electrode Development. Previously, Dr. Diaz-Botia led the microfabrication process engineering team at Neuralink Corp., a Company founded by Elon Musk, working on developing a high bandwidth brain machine interface.
“We are thrilled to have such a highly regarded neural engineering expert to lead our development team,” says Dave Rosa, president and CEO, NeuroOne. “Camilo brings in-depth knowledge and expertise in the design of implantable thin film electrodes. His responsibilities and experience at Neuralink, from research and development to manufacturing, expand the depth and breadth of our capabilities to further develop NeuroOne’s portfolio of thin film electrode technology. As we continue to pursue our vision of developing combination diagnostic and therapeutic electrode technology, we expect Camilo’s leadership and experience will contribute significantly to helping us achieve these goals.”
At Neuralink Corp., Dr. Diaz-Botia led and mentored the process engineering team to deliver projects with unique microfabrication processes. Under his direction, the team built and designed novel processes for integration of thin film neural probes with brain machine interface systems.
Dr. Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from the joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin film neural interfaces for chronic implants developing electrocorticography arrays with silicon carbide, a material suitable for long-term performance in harsh environments, and electrode arrays for minimally invasive subcortical recordings. He has authored and co-authored multiple peer reviewed scientific articles published in journals including Journal of Neural Engineering, Neuron and Lab-on-a-Chip.
Dr. Diaz-Botia states, “I believe NeuroOne’s focus on bringing thin-film devices to patients will have a significant impact in their overall clinical experience. For many years, thin film technologies have been utilized in academic settings and have matured enough to address a number of clinical needs today. I am excited to be a part of the ongoing development of NeuroOne’s thin film electrodes and furthering NeuroOne’s goal of making these devices commercially available.”
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, essential tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs. Visit https://www.n1mtc.com/.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s regulatory submissions, potential regulatory approval, commercialization of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market acceptance of our products, clinical trial patient enrollment, the results of clinical trials, future competition, the actions of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward‐looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the order of a physician.”
201.641.1911 x 14
Investor Relations Contact:
Sr. Director of Marketing
NeuroOne Medical Technologies Corporation
Source: NeuroOne Medical Technologies Corporation